Negative Pressure Wound Therapy (NPWT) (procedure and medical aid)

Series
Dermatology
Status
Published
Date
Number of report
088

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of negative pressure wound therapy (NPWT) (procedure and medical aid) in European countries.

The following clinical indications will be considered:

  • Diabetic foot ulcer;
  • Venous leg ulcer;
  • Pressure ulcer.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices of Negative Pressure Wound Therapy include:

  • Acelity (V.A.C.)
  • Cardinal Health (Ally, ATG, PRO, Catalyst, SVED, Irrigation)
  • Carilex Medical (VT 200, VT ONE)
  • ConvaTec (Avelle)
  • Cork Medical (Nisus)
  • DeRoyal (Prospera PRO, Prospera Mini)
  • Devon MD (ExtriCARE2400, ExtriCARE3600, ExtriCARE)
  • Genadyne (XLR8 & XLR8 Plus)
  • Lohmann & Rauscher (Suprasorb)
  • Medela (Invia Liberty, Invia Motion, Invia)
  • Smith & Nephew (Pico)
  • Talley Group (Venturi Avanti, Venturi Compact, Venturi Mino)
  • Triage Meditech (VTG 2901)

Table of content is not available at the moment. Report is still ongoing.

01

Apr 2020

The report presents a summary of the reimbursement situation for the use of negative pressure wound therapy (NPWT) (procedure and medical aid) in Europe. The following clinical indications are considered: diabetic foot ulcer; venous leg ulcer; pressure ulcer. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

20

Sep 2019

The report presents a summary of the reimbursement situation for use of biologic and synthetic skin substitutes in Europe. The following clinical indications are considered: burns; chronic wounds (hypertrophic scar). The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

20

Sep 2019

The report presents a summary of the reimbursement situation for treatment of burns in Europe. The following types of treatment for burns of are considered: debridement of burn skin; dressing of burnt skin (including vacuum assisted closure device); placement of split-thickness skin autograft. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more
(we accept only company emails)